Particularly, we had chosen: ralimetinib (LY2228820), a selective inhibitor of α- and β-isoforms of p38-MAPK tested in phase I trial with radiotherapy plus concomitant TMZ in the treatment of newly diagnosed GBM [23]; ulixertinib (BVD-523), a reversible, ATP-competitive, catalytic ERK1/2 inhibitor, currently tested in a clinical phase II trial with pediatric patients with MAPK pathway mutations and pediatric patients with relapsed solid and brain tumors [24]. The gene discussed is MAPK3; the disease is brain neoplasm.